Genesis Therapeutics’ Post

Curious about GenAI research we do at Genesis? Our Director of ML Research, Maruan Al-Shedivat, PhD, gave a great talk at ICML that highlights Genesis’ pioneering work on modeling biomolecular systems at atomic precision and fidelity. Watch the recording to learn about some of the challenges in our field and see how our team leverages diffusion-based generative models to drive forward small molecule drug discovery. Check it out here: https://lnkd.in/gUQdT8EA

Allison Keys (Massachusetts Institute of Technology, PhD Class of 2025) was one of the Summer 2024 Computational Chemistry interns. Read more about her experience and consider applying for one of our open internship or full-time positions: https://lnkd.in/gjJQCYJk.

Justin Steinman (University of Massachusetts Amherst, Class of 2025) was one of our Summer 2024 Software Engineering interns. Learn more about his experience and consider applying for one of our open internship or full-time positions: https://lnkd.in/gjJQCYJk.

We’re thrilled to announce our collaboration with Gilead! Together, we’re combining forces to accelerate groundbreaking discoveries and push the boundaries of what’s possible in drug development. This partnership highlights the power of our AI platform, GEMS, and our shared commitment to creating innovative and breakthrough medicines for patients with high unmet medical need. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies | Business Wire https://lnkd.in/g6d_gFBA

The Genesis team is excited to be attending #ICML2024 in Vienna this week, July 21-27. We’re proud to be sponsoring ML4LMS as well as the SPIGM Workshop where our Director of Machine Learning, Maruan Al-Shedivat, PhD, will be giving a talk on Generative Modeling in Drug Discovery. If you’re at ICML, we’d love to connect with you - if you would like to chat with a member of our technical team, sign up here: http://bit.ly/4dcTuiw

We are honored to be named one of Fierce MedTech's 2023 Fierce 15 companies! Congratulations to the Genesis team for the well-deserved recognition of their work as pioneers of AI-enabled drug discovery to find transformational medicines for patients. Read the full article here, including an interview with our CEO, Evan Feinberg, on what makes Genesis fierce: https://lnkd.in/eUDaU-Nm

Yesterday, Genesis's CTO and co-founder Ben Sklaroff spoke at Biocom California about the potential of AI to unlock undruggable targets and help surface novel molecules that could become breakthrough therapies for patients. Learn more about how Genesis is pioneering generative and predictive AI for drug discovery here: https://lnkd.in/g_jdaiYN

Evan Feinberg at the #WuxiGlobalForum

Next week, Genesis’ CEO, Dr. Evan Feinberg, PhD, will speak at the 2024 WuXi AppTec Global Forum alongside fellow industry leaders to discuss how platform solutions, such as Genesis’ AI-enabled drug discovery platform, are driving the development of medicines that improve the lives of patients living with difficult-to-treat disease. Learn more about the panel, “Delivering on Platform Solutions,” and the forum here: https://lnkd.in/ggbqGe2F